Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A shock US rejection delays approval by at least two years and makes Abbvie, which had given up rights five years ago, look smart.
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.